Skip to main content
Premium Trial:

Request an Annual Quote

Edward Rubin Named to JGI s Top Spot

SAN FRANCISCO, Jan. 28 - Edward Rubin has shed his "acting" status and was named director of the US Department of Energy's Joint Genome Institute, the institute said today.


Rubin was also appointed director of the Lawrence Berkeley National Laboratory's genomics division.


Rubin held the position of interim director of JGI since spring 2002, taking over leadership responsibilities from Trevor Hawkins who left for an executive position at Amersham Biosciences.


The appointment follows an approximately five-month search process, according to a JGI spokesperson.


Rubin joined LBNL in 1988 and was appointed head of the lab's genome sciences department in 1998. His most recent research has focused on identifying regions of the human genome encoding for significant biological functions by conducting large-scale cross-species DNA sequence comparisons.


JGI is managed by Lawrence Berkeley National Laboratory, Lawrence Livermore National Laboratory, and Los Alamos National Laboratory.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.